FDA Panel Reschedules Review of Troubled Muscular Dystrophy Drug Eteplirsen

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has announced that it will discuss the new drug application for eteplirsen (Sarepta Therapeutics) on April 25––nearly three months after the original action date. Sarepta is seeking approval for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

On January 15, FDA staff said they were unconvinced about eteplirsen’s efficacy and trial design, a day after the agency rejected rival drug drisapersen (Kyndrisa, BioMarin Pharmaceutical) for insufficient efficacy.

There are no FDA-approved drugs for DMD, and pressure has been mounting on the FDA to quickly approve treatments.

Three years ago, Sarepta’s CEO claimed that the company was making progress in convincing the FDA to accept dystrophin production as a surrogate marker that could be used for early approval. But Sarepta’s data on walking distance in boys were taken from a tiny study, and an internal review by FDA staff dismissed the company’s findings out of hand.

As of now, analysts give eteplirsen little chance of being approved when it comes up for a formal decision.

Sources: Reuters; March 10, 2016; and FierceBiotech; March 10, 2016.

More Headlines

Study shows how mindfulness meditation reduces pain
FDA Approves New Hemophilia Therapy
Bayer AG’s Kovaltry joins a crowded field
Study: One in Four Seniors Carries ‘Superbugs’ From Hospitals to Post-Acute Care Settings
It’s time patients started washing their hands, author says
Takeda Dumps Obesity Drug Contrave (Naltrexone/Bupropion)
Company sets sights on antidepressant and IBD markets
Potential Zika Virus Risk Estimated for 50 U.S. Cities
Mosquitoes flourish in summer months
CDC Issues Guideline for Prescribing Opioids for Chronic Pain
Agency responds to overdose epidemic
U.S. scientists see potential for widespread outbreak
Report: Using Generic Cancer Drug Could Save Millions of Dollars
Johns Hopkins team shines spotlight on generic imatinib
Hospital Pharmacists Pitch In to Improve Care While Keeping Costs Down
Pharmacy departments facilitate transition of care

Our most popular topics on Managedcaremag.com